Can-Fite’s namodenoson meets safety endpoint in Phase IIa pancreatic cancer trial
CANF•Can-Fite BioPharma presented final Phase IIa results for namodenoson in advanced pancreatic cancer at ESMO 2026 in Madrid. The trial met its primary safety endpoint, with mild-to-moderate treatment-related adverse events and none requiring treatment changes.
1. Trial results
Exploratory survival findings supported further clinical development, but the selected patient subgroup and lack of a randomized comparison limit conclusions.
